76
|
Lee S, Song Y, Park K, Kwon J, Kim B, Kim H, Lee C, Yu J, Hong S. Influence Of Farm Childhood On Allergic Diseases And Atopy. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
77
|
Lee H, Jeon E, Bang B, Shim E, Kwon J, Kim T, Jung J, Lee S, Kim K, Kim S, Kang H, Park H, Chang Y, Kim S, Cho S, Min K, Kim Y. TNF-α Contributes To The Development Of Asthma By Enhancing IL-23/Th17 And Th2 Immune Responses. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
78
|
Kang M, Kim B, Kwon J, Kim T, Jung J, Lee S, Kim K, Kim S, Kang H, Park H, Chang Y, Kim S, Cho S, Min K, Kim Y. Clinical Characteristics of Kimura Disease in Korea. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.724] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
79
|
Kwon J, Kang M, Kim B, Choi W, Ryu M, Kim M, Yu J, Hong S. Polymorphisms of the GSDMA and GSDMB are Associated with Asthma Susceptibility, Atopy and Bronchial Hyperresponsiveness. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
80
|
Seo J, Choi W, Kang M, Kim B, Kwon J, Kim J, Kim B, Yu J, Hong S. Gene-gene Interaction among Candidate Gene Polymorphisms is Associated with Total IgE Levels in Children with Asthma. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
81
|
Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. ACTA ACUST UNITED AC 2010; 15:126-35. [PMID: 18596890 PMCID: PMC2442763 DOI: 10.3747/co.v15i3.204] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Question What is the role of hormonal therapy as adjuvant therapy in patients with stage i endometrial cancer? Perspectives There is little consensus on the role of adjuvant treatment for patients with stage i endometrial cancer. Although the use of hormonal therapy has been established in advanced disease, less agreement has emerged concerning the benefits of adjuvant hormonal therapy for patients with early-stage disease. The objective of the present evidence series was to review the existing literature on the role of hormonal therapy as adjuvant therapy in patients with stage i endometrial cancer. Outcomes Reports were sought that included at least one of the following outcomes: overall survival, disease-free survival, recurrence (local, or distant, or both), adverse effects, and quality of life. Because of the potential for long-term adverse effects with adjuvant hormonal treatment in this patient population, especially with regard to thromboembolic or cardiovascular events, the rates of non-cancer-related death were also of interest. Methodology The medline, embase, and Cochrane Library databases were systematically searched for randomized controlled trials, practice guidelines, systematic reviews, and meta-analyses. The resulting evidence informed the development of the clinical practice guideline. The systematic review with meta-analyses and practice guideline were approved by the Report Approval Panel of the Program in Evidence-Based Care, and by the Gynecology Cancer Disease Site Group (dsg). Results Nine randomized trials and one published meta-analysis comparing adjuvant hormonal therapy with no adjuvant therapy in women with stage i endometrial cancer constituted the evidence base. One trial reported a statistically significant survival benefit with adjuvant progestogen as compared with no further treatment (97% vs. 69%, p < 0.001). In that trial, the treatment group had a higher number of patients with less myometrial invasion, and a lower number of patients with advanced-stage disease. These differences in baseline characteristics between the randomized groups were considered to be clinically important. In addition, the results of that trial were not consistent with those of other trials, and the trial was a source of statistical heterogeneity when data were pooled across trials. In two of the nine randomized trials, statistically significant recurrence-free benefits were detected with adjuvant hormonal therapy as compared with no further therapy. In one trial, the difference between the rates of recurrence was 16%; however, the methodologic concerns related to that that trial limited its relevance. In the other trial, the difference between the rates of recurrence was 5%. In that trial, patients were at a high risk of recurrence. None of the remaining seven randomized trials reported any significant difference in recurrence rates between treatment groups. The meta-analysis identified in the literature detected no statistically significant recurrence-free or overall survival benefit associated with adjuvant hormonal therapy as compared with no adjuvant therapy [odds ratio (or): 1.05; 95% confidence interval (ci): 0.88 to 1.24). Those results are consistent with the results of the meta-analysis in the present report, which included an additional two trials (or: 1.10; 95% ci: 0.91 to 1.34). Practice Guideline
Collapse
|
82
|
Lee E, Son G, Kwon J, Kim Y, Lee B, Park Y. P907 Pregnancy outcome according to maternal weight gain rate by trimester. Int J Gynaecol Obstet 2009. [DOI: 10.1016/s0020-7292(09)62395-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
83
|
Lee Y, Cho S, Kim J, Kwon J, Yun S, Yun H, Shin J. UP-1.193: A Comparison among Suprapubic Arc Sling, Transobturator Tape Placement and TVT-Secur® Operation in Women with Stress Urinary Incontinence. Urology 2009. [DOI: 10.1016/j.urology.2009.07.640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
84
|
Chung S, Park Y, Jeon S, Kim Y, Kwon J. P225 The influence of delivery mode on the regression of abnormal cytology of cervix. Int J Gynaecol Obstet 2009. [DOI: 10.1016/s0020-7292(09)61715-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
85
|
Lee Y, Shin J, Cho S, Kim J, Kwon J, Yun S, Yun H. UP-2.030: Effects of Subclinical Prostatitis in Prostate Needle Biopsies on the Serum Prostate Specific Antigen: The Role of Pathology of Inflammation. Urology 2009. [DOI: 10.1016/j.urology.2009.07.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
86
|
Zang D, Kang Y, Ryu B, Ryu M, Lee S, Kim H, Kim J, Jung J, Kwon J, Kim H. 6546 Phase II study of docetaxel, oxaliplatin and S-1 (DOS) for patients with advanced gastric cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71268-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
87
|
Kwon J, Park J, Lee D, Kim YS, Jeong HJ. Toll-like receptor expression in patients with renal allograft dysfunction. Transplant Proc 2009; 40:3479-80. [PMID: 19100417 DOI: 10.1016/j.transproceed.2008.06.073] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2008] [Accepted: 06/27/2008] [Indexed: 11/16/2022]
Abstract
Toll-like receptor (TLR) is known to be a mediator of innate immunity, but recent reports have shown that TLR provides a link to adaptive immunity involved in allograft rejection. To explore the expression patterns in various conditions of renal transplantation, we examined TLR subunit mRNA expressions in renal allograft biopsies of acute rejection (AR; n = 11), chronic rejection (CR; n = 15), chronic cyclosporine nephrotoxicity (CsAN; n = 22), and immunoglobulin A nephropathy (IgAN; n = 9) patients. Control tissues (n = 7) were obtained from normal renal cortical tissue of renal cell carcinoma patients. The diagnosis was made according to the Banff 97 classification. The expressions of TLR 2, 3, 4, and 9 mRNA were analyzed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) using SYBR green. Statistical analysis was performed using analysis of variance (ANOVA) and the Student t test. TLR 2 and 3 mRNA expressions were not significantly different in any group (P > .05). In contrast, TLR 4 mRNA expression was significantly increased in all allograft groups compared with that of controls, and significantly higher in the CsAN than other transplant groups (P < .05). TLR 9 mRNA expression was up-regulated in CsAN and IgAN compared with AR and CR (P < .05). These results suggested that TLR4 mRNA expression was increased in renal allograft patients with chronic allograft dysfunction. Further studies are needed to correlate TLR subtypes with various causes of graft dysfunction among renal allograft patients.
Collapse
|
88
|
Elit L, Schultz S, Prysbysz R, Kwon J, Saskin R, Gunraj N, Wilton AS, Simunovic M, Urbach D. Patterns of surgical care for uterine cancers in Ontario. EUR J GYNAECOL ONCOL 2009; 30:255-258. [PMID: 19697615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
OBJECTIVES To facilitate the planning of future resources for cancer services in Ontario, Cancer Care Ontario commissioned an evaluation of operative services delivered for uterine cancer. METHODS Women with an incident diagnosis of a uterine malignancy were identified from 1 April 2003 to 31 March 2004 using the Ontario Cancer Registry. Record linkages were created to other provincial health databases such as the Ontario Health Insurance Plan. RESULTS Uterine cancer affected 1,436 women. Disease specific rates of cancer were higher in rural areas and those from the highest income quintiles. Surgery occurred in 94.7% of women. Use of surgery did not appear to vary by SEC, urban/rural residence or LHIN. Gynecologists conducted 76.1% of the operations. Lymphadenectomy took place in 18.7% of women. Lymphadenectomy rates were highest in gynecologic oncologists (43.3%). All women were assessed by CXR. Radiation therapy consults were preformed in half of the women with uterine cancer but treatment was only delivered in half of those seen. Medical oncologists saw about 6.3% of women with uterine cancers. CONCLUSIONS There appear to be variations in incidence rates of uterine cancer with disease being more frequent in those of the highest SES. In two-thirds of the population, surgery is delivered in the region where the patient lives. Subspecialty care from gynecologic oncologists was provided to one-third of women. Rates of lymphadenectomy as part of a surgical attempt to assess disease spread appear low. These pilot data would be enhanced with further information such as comorbidity, treatment intent (palliative/curative), histology, grade and stage.
Collapse
|
89
|
Senanayake V, Juurlink BH, Zhang C, Zhan E, Wilson LD, Kwon J, Yang J, Lim ZL, Brunet SMK, Schatte G, Maley JM, Hoffmeyer RE, Sammynaiken R. Do Surface Defects and Modification Determine the Observed Toxicity of Carbon Nanotubes? J Biomed Nanotechnol 2008. [DOI: 10.1166/jbn.2008.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
90
|
Lupe K, D'Souza D, Kwon J, Gawlik C, Whiston F, Carey M. Adjuvant Carboplatin and Paclitaxel Chemotherapy with Involved Field Radiation for Advanced Endometrial Cancer. Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.1199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
91
|
Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Yu J, Kerr RO, Saif MW. Phase II clinical trial of paclitaxel loaded polymeric micelle (GPM) in patients (pts) with advanced pancreatic cancer (APC): Final results. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4627] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
92
|
Lee H, Ahn M, Ahn J, Kwon J, Lee S, Bae S, Kim B, Kim H, Hong D, Park K. Pemetrexed monotherapy in patients with advanced non-small cell lung cancer who have had prior chemotherapy: A prospective phase II trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
93
|
Jung J, Park S, Kwon J, Kim J, Kim H, Song H, Kim H, Zang D. A phase II study of splited 5-fluorouracil and cisplatin (split FP) against advanced or metastatic hepatocellular carcinoma (HCC): Preliminary results. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
94
|
Lim Y, Kim T, Kwon J, Kim D, Lee S, Kwon B, Hong J, Yun Y. OBOVATOL INHIBITS INTIMAL HYPERPLASIA AFTER CAROTID ARTERY INJURY BY INDUCTION OF P21 PROTEIN. ATHEROSCLEROSIS SUPP 2008. [DOI: 10.1016/s1567-5688(08)70255-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
95
|
Zang D, Yang D, Lee H, Lee B, Hwang S, Kim H, Song H, Jung J, Kim J, Kwon J. 3557 POSTER Phase I study of docetaxel, oxaliplatin and S-1 (DOS) for patients with advanced gastric cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71060-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
96
|
Lee K, Jang H, Choi M, Kong J, Lee S, Kwon J, Nam E, Mun Y, Seong C, Lee S. Clinical analysis of multiple primary cancers. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.19639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
19639 Background: Multiple primary cancers are defined as two or more abnormal growths of tissue occurring simultaneously or abnormal growths of tissues that follow a previous neoplasm but are not metastases of the latter in the same individual. The primary objective of this study was to determine the occurrence, clinical characteristics and prognosis of multiple primary cancers in single institution, respectively. Methods: Between January 1995 and June 2006, patients with multiple primary cancers were selected from a review of patients who had been treated and followed-up in our Ewha Womans University Hospital. Demographic data were obtained from medical records. Results: Two hundred seven patients were selected and patients with multiple primary cancers constituted 1.95% of all malignancies. Male to female ratio was 1.84. (male 134 vs. female 73 patients) The median age first cancer diagnosis was 67 years old in male, 57 in female. The incidence of synchronous cancers is higher than metachronous. (108 vs. 99) and the median time to additional cancers in metachronous group was 35 months. The most frequent cancers was gastrointestinal cancers in both sex synchronously and metachronously. In male, colorectal cancer followed by gastric cancer methchronously (9.1%), genitourinary cancer with another genitourinary cancer synchronously (12.7%) were frequently observed. In female, breast cancer followed by colorectal cancer metachronously (6.8%), gastric cancer with colorectal cancer (6.9%) were frequently observed. The median survival duration was 14.4 months totally from the index diagnosis and synchronous cancers showed lower survival duration than metachronous cancers. (7.4 vs. 26.1 months, p=0.017) Conclusions: Adequate investigations including G-I tract should focus in the first 3 years after initial diagnosis to detect second primary cancers earlier. No significant financial relationships to disclose.
Collapse
|
97
|
Murray T, Derrah L, D'Souza D, Yuen J, Batchelar D, Kwon J, Sugimoto A, Carey M, Lock M. 156 Gynaecologic HDR Interstitial Brachytherapy: The Role of Radiation Oncology Nursing in Multi-disciplinary Care. Radiother Oncol 2006. [DOI: 10.1016/s0167-8140(06)80897-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
98
|
Lupe K, Kwon J, D'Souza D, Carey M, Gawlik C, Stitt L, Whiston F. 93 A prospective study of adjuvant carboplatin and paclitaxel chemotherapy and involved field radiation in women with high risk endometrial cancer. Radiother Oncol 2006. [DOI: 10.1016/s0167-8140(06)80834-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
99
|
Kwon J, Suzuki T, Kumagai S, Shinkai S, Yukawa H. Risk factors for dietary variety decline among Japanese elderly in a rural community: a 8-year follow-up study from TMIG-LISA. Eur J Clin Nutr 2006; 60:305-11. [PMID: 16234831 DOI: 10.1038/sj.ejcn.1602314] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE To examine the factors related to the decline of dietary variety among the rural community-dwelling Japanese elderly people and the implication on the planning of elderly people's nutritional improvement program in the future. DESIGN A prospective cohort study during 8-year follow-up from 1992 to 2000. SETTING This study was conducted in Nangai Village, a rural and mainly agricultural area of Akita Prefecture in the northern part of Honshu, one of four main islands in Japan. SUBJECTS A total of 417 elderly people (160 men, 257 women) who completed interviews and food intake frequency surveys conducted in 1992, 1994, 1996, 1998, and 2000 were studied. METHODS Dietary variety and variables potentially associated with dietary variety decline were identified from a face-to-face interview at the baseline and 8-year follow-up surveys. The dietary variety was measured using the dietary variety score (DVS), which covers the 10 main food groups in Japanese meals. RESULTS During the 8-year follow-up, 36.2% of the subjects showed a decline in dietary variety. Health characteristics also change among the 8-year follow-up and these changes have an effect on the decline of dietary variety. Significant predictors for decline in dietary variety included loss of spouse, deterioration in self-perceived chewing ability, and decrease in intellectual activity score. CONCLUSIONS Loss of spouse, deterioration in chewing ability, and decline in intellectual activity may increase the risk of decline in dietary variety in community-dwelling Japanese elderly people.
Collapse
|
100
|
Jang H, Park J, Kwon J, Jung J, Kim H, Song H, Zang D, Lee J, Park Y, Kim J. A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17115 Background: The combination of gemcitabine and cisplatin is among the most active regimens for the treatment of NSCLC. However, the optimal dose and schedule for administration of the two drugs has not yet been determined. We investigated the activity and toxicity of a gemcitabine and split-dose cisplatin regimen in an outpatient setting for patients with advanced non-small cell lung cancer (NSCLC). Methods: From June 2004 to May 2005 patients with stage IIIB or IV who had not had prior chemotherapy entered the study. Treatment consisted of gemcitabine 1,250 mg/m2 and cisplatin 35 mg/m2, both given intravenously on days 1 and 8 every 21 days. Results: Forty-three patients were entered this study. Patient characteristics were as follows: male/female, 32/11; median age (range), 63 (30–76) years; ECOG PS 0/1/2, 7/28/8; stage IIIB/IV, 17/26. A total of 160 cycles were delivered, with a median of 4 cycles (range, 1–6). All patients were evaluable for toxicity. Grade 3 & 4 toxicities according the NCI toxicity criteria included included neutropenia in 7 patients (17%), anemia in 3 (7%), thrombocytopenia in 6 (14%), and emesis in 1 (2%). Of 40 patients assessable for response, one (2.5%) had CR and 22 (55%) had PR. On intent-to-treat basis, the overall response rate was 53% (95% CI, 39–68%). Median time to progression was 6.0 months (range, 1.2–12.0 months) and median overall survival was 13.1 months (range, 1.4–17 months). Conclusions: This regimen with gemcitabine and split-dose cisplatin using a 21-day schedule appears to be active and very well-tolerated in an outpatients setting for patients with advanced NSCLC. No significant financial relationships to disclose.
Collapse
|